

its cytotoxic biological activity neutralized by antisera raised against human glycosylated TNF- α , to a replicable expression vehicle to obtain a replicable recombinant DNA comprising said DNA and said replicable expression vehicle;

(b) transforming eukaryotic cells with said replicable recombinant DNA to form transformants;

(c) culturing said transformants to cause said transformants to express said glycosylated human TNF- α ; and

(d) isolating said glycosylated human TNF- α from the cultured transformants.

3 (Amended). The method according to claim 2, further comprising the step of purifying the isolated glycosylated human TNF- α .

5 (Thrice-amended). A composition consisting essentially of glycosylated human tumor necrosis factor-alpha (TNF- α) having cytotoxic biological activity and at least one pharmaceutically acceptable carrier, diluent, or excipient.

6 (Twice-amended). In the method for treating a human disease or condition treatable by the administration of an effective amount of human tumor necrosis factor-alpha (TNF- α) alone or in combination with other active principles or inactive carriers, diluents or excipients, the improvement wherein said human TNF- α is glycosylated human TNF- α exhibiting cytotoxic biological activity.

7 (Amended). A method in accordance with claim 2, wherein said DNA encoding human TNF- α or a mutant thereof encodes human TNF- α .